Tag - KZR

Developments

Kezar doses first patient in advanced solid tumor malignancies study

Kezar Life Sciences (NASDAQ:KZR) dosed the first patient in a Phase 1 clinical trial evaluating KZR-261, a broad-spectrum, anti-tumor agent that acts through direct interaction and inhibition of the Sec61 translocon...

October 27, 2021

Feature

Kezar Life Sciences harnessing master regulators of cellular functions to tackle disease

Kezar Life Sciences (NASDAQ:KZR) is advancing two drug development programs that have the potential to address a number of indications by harnessing different “master regulators” of cellular function: protein...

March 9, 2021

Developments

Kezar KZR-616 gets FDA orphan drug designations for two autoimmune disease

Kezar Life Sciences’ (NASDAQ:KZR) KZR-616 received FDA orphan drug designation for the treatment of polymyositis and dermatomyositis, autoimmune inflammatory myopathies with marked morbidity and mortality. KZR-616 is a...

October 23, 2020

Tag - KZR

Kezar doses first patient in advanced solid tumor malignancies study

Kezar Life Sciences harnessing master regulators of cellular functions to tackle disease

Kezar KZR-616 gets FDA orphan drug designations for two autoimmune disease

General

More